Dr Pascale Tomasini talks to ecancer at ESMO 2024 about the the study she presented looking at precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitor resistance

The phase 1b /2a PIONeeR trial was able to explore several options to overcome resistance to immune checkpoint inhibitors. Although no experimental arm performed better than outcomes observed with docetaxel, some patients had long duration of response, suggesting durvalumab combinations can be highly effective.

Biomarker work is ongoing to identify patients most likely to benefit from combination treatment.